Abstract
Across the world, countries are fighting to reduce the spread of COVID-19. The backbone of the response is a test-trace-isolate strategy, where suspected infected get tested and isolated and possible secondary cases get traced, tested and isolated. Because more accurate tests often take longer to analyze, and the benefits of contact tracing are strengthened by rapid diagnosis, there exists a trade-off in test sensitivity and test waiting time in test-trace-isolate strategies. Here we ask: How many false negatives can be tolerated in a rapid test so that it reduces transmission better than a slower, more accurate test? How does this change with contact tracing efficiency and test waiting time? We find that a rapid, less sensitive test performs best for many test-parameter choices and that this is true even for modest contact tracing efficiency. For COVID-19-like viral parameters, a test with 40% false negatives and immediate result might reduce transmission as well as a test with no false negatives and a 3-day waiting time. Our analysis suggests employing rapid tests to reduce test waiting times as a viable strategy to reduce transmission when testing infrastructure is under stress.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partially funded by Statens Serum Institut (SSI).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Cornell University
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The code and data necessary to reproduce the content of this paper is available on www.github.org/jonassjuul/TestTraceTradeoff
